Astellas announces availability of enzalutamide prostate cancer medication in UK
Administered without the need for routine product-specific monitoring, Enzalutamide works at three steps in the androgen receptor (AR) signalling pathway within the cancer cells terminating the cancer growth.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.